

### Christian Rønn Hansen

Odense University Hospital. Laboratory of Radiation Physics. Odense. Denmark. University of Southern Denmark. Institute of Clinical Research. Odense. Denmark. School of Physics - The University of Sydney. Institute of Medical Physics. Sydney. Australia.

# Clinical Experience with Philips Auto-Planning

Mail: christian.roenn@rsyd.dk



### Disclosure

- Danish Cancer Society
- Danish Cancer Research Fund
- Odense University Hospital University of Southern Denmark



# Aims and challenges of automated planning

### Aims

- Increase treatment plan quality
- Handle high treatment plan complexity
- Better efficiency
- Reduce inter planner variation

### Challenges

- Multi center use of Autoplan
- Overlapping PTVs with OAR
- PTV target in air or near surface
- Large density differences in target areas
- Dose distribution and conformity for stereotactic patients



### How does Autoplan work

- Mimic treatment planner
- Evaluate plan according to protocol
- Fine tune objectives





	Structure	Dose con- straint OAR [Gy]	SHOUL	Cochlea	D <sub>mean</sub> ≤ 45Gy og D <sub>3%</sub> ≤ 55Gy		
ABSOLUTE	Brain stem	D <sub>max</sub> ≤ 54Gy		Parotid gland	<ol> <li>Contralateral parotid:</li> <li>D<sub>mean</sub>≤ 20Gy</li> <li>Both parotids: D<sub>mean</sub></li> <li>≤26Gy</li> </ol>		
				Mandible	Hotspots in the mandible should be avoided	DAHANCA Radiotherapy	Guidelines 2013 – English version 2.0, January 30th 2015
	Spinal cord	D <sub>max</sub> ≤ 45Gy	CAN	Pituitary gland	D <sub>mean</sub> ≤30Gy	Radiothera	HANCA Py Guiden
<u>S</u>	Anterior eye (conjunctiva,	D <sub>max</sub> ≤30Gy		Brain	D <sub>max</sub> ≤ 60Gy		013 <sup>Adennes</sup>
ST	lacrimal gland, cornea, iris)*			Submandibular gland Oral cavity	D <sub>mean</sub> ≤ 35Gy D <sub>mean</sub> ≤ 30Gy for non-		
	Chiasm and optic	D <sub>max</sub> ≤ 54Gy		Lips Larynx	involved oral cavity D <sub>mean</sub> ≤ 20Gy D <sub>mean</sub> ≤44 Gy	DAHANCA	
	nerve			Thyroid gland	D <sub>mean</sub> <40 Gy		
	Posterior eye	D <sub>max</sub> ≤ 45Gy					09-07-2018
	(retina)			Oesophagus	D <sub>mean</sub> ≤ 30Gy	RADIOTHERAPY & ONCOLOGY	ESTRO

Treatment Techniques											
File	que Name Hteam_66_60_50_FINAL Trial to Create	?									
Planning Beams Auto-Plan Descri	Hteam_66-60-50	Help									
Auto-Planning Settings	Organ At Risk (OAR) Optimization Goals										
Max Iterations Engine Type	ROI Type Dose Volume Gy (RBE) (%) Priority	Compromise									
₹50 ◆ Biological	◆ BrainStem ✓ Max Dose → 54 High										
Advanced Settings											
Scorecard											
H_Hals666050_FINAL		- 7									
Target Optimization Goals											
ROI Gy (RBE)	↓ Šubmand_R     ✓ Mean Dose     ↓     35     High	- 7									
	↓ Submand_L     ✓ Mean Dose     ↓     35     High										
	↓ LarynxSG      ✓ Mean Dose      ↓     130     High										
	→ LarynxG I Mean Dose I 30 High										
	OralCavity     Mean Dose     I i an     Hinth										
Add Delete Add Delete											

Create Technique from Current Trial

Apply and Optimize

# Autoplan Odense

- Autoplan is clinical standard for:
  - H&N
  - Brain
  - Esophagus
  - Bladder (adaptive triple plan generation)
  - Prostate
  - Cervix
  - Rectum
  - Hippocampus sparing whole brain
  - Conformal palliation
- Still challenging cases
  - Lung
  - SBRT Lung



### H&N - step and shoot IMRT

- 30 H&N patients
- Autoplan sparing OAR better
- Reduced inter planner variation





#### Hazell et al. J Appl Clin Med Phys. 2016



### Blinded implementation of Autoplan on H&N

- First 30 clinical Autoplan patients
  - Manual VMAT plan create
  - Autoplan VMAT plan create
    - No comparison between the plans before after they were final
  - Blinded for evaluations
  - Best plan selected for treatment
  - > 29 of 30 plans treated were Autoplan
  - > The operator time is reduced by a factor of 2 (60 min 30 min)

Hansen et al. Clin Transl Radiat Oncol. 2016





### H&N Manual vs Autoplan Population mean DVH

30 patients

0.9

0.8

0.7

0.6

0.5

0.4

0.3

0.2

0.1

0

0

10

Relative volume, p-value





### Plan comparison H&N

#### Manual

#### **Autoplan**





#### Sparing of Organ at Risk for H&N

		Autop	lan	Manu	ıal		
OAR	Unit	Mean	STD	Mean	STD	Difference	Р
Spinal cord	[Gy]	20.2	6.9	22.9	5.8	-2.7	< 0.001
Brainstem	[Gy]	3.5	4.0	5.1	4.7	-1.6	< 0.001
Oral cavity	[Gy]	31.6	13.3	34.3	12.8	-2.7	< 0.001
Libs of mouth	[Gy]	12.3	7.7	15.2	6.8	-2.9	< 0.001
Parotid gland ipsi*	[Gy]	23.4	16.4	25.5	15.7	-2.1	< 0.001
Parotid gland con**	[Gy]	18.5	8.1	20.5	8.8	-2.0	0.004
Submandibular gland ipsi*	[Gy]	53.2	11.4	56.0	7.7	-2.8	0.01
Submandibular gland con**	[Gy]	34.0	19.2	40.5	18.9	-6.5	0.0001
Mandible	[Gy]	30.2	9.4	32.3	8.9	-2.1	0.0002
Thyroid gland	[Gy]	34.6	13.3	37.1	11.2	-2.5	0.0007
Larynx	[Gy]	39.1	9.4	44.8	8.7	-5.7	0.0004
Body	[Gy]	9.3	3.0	9.8	2.9	-0.5	< 0.001

#### ~10% dose reduction



### Prostate

50 Patients78 Gy in 39 fractionsSelect Manual vs Autoplan

Results

- Gains like H&N
- Spare Rectum. Bladder. Bowel and femur head better
   Manual
   Autoplan





### Prostate Manual vs Autoplan Population mean DVH



### Autoplan for Esophagus

32 Patients 60-50 Gy in 30 fractions Select manual vs Autoplan

#### **Results**

- Automatic treatment planning facilitates fast generation of high-quality Automatic treatment planning facilitates fast generation of high-quality 31/32 Autoplan were selected
- Spare lung much better.
- Heart dose can go up.
- Auromatic treatment planning factifiate. treatment plans for esophageal cancer Mean cord dose goes up.

# Moren Nielsen<sup>®</sup>, <sup>Inders Smedegaard Berrelsen<sup>®</sup>, <sup>Irene</sup> Hazell<sup>®</sup>, <sup>Era Holtwee<sup>t</sup></sup>, <sup>Irene Hazell<sup>®</sup>, <sup>Era Holtwee<sup>t</sup></sup>, <sup>Irene Hazell<sup>®</sup>, <sup>Era Holtwee<sup>t</sup></sup>, <sup>Irene Berrehou<sup>ss</sup></sup> and <sup>Irene Berrehou<sup>ss</sup></sup> and <sup>Irene Hazell<sup>®</sup>, <sup>Era Holtwee<sup>t</sup></sup>, <sup>Irene Berrehou<sup>ss</sup></sub> and <sup>Irene Berrehou<sup>ss</sup></sup>, <sup>Irene Hazell<sup>®</sup>, <sup>Era Holtwee<sup>t</sup></sup>, <sup>Irene Berrehou<sup>ss</sup></sub> and <sup>Irene Berrehou<sup>ss</sup></sup>, <sup>Irene Hazell<sup>®</sup>, <sup>Irene Hazell</sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup></sup> Christian Romn Hansen & Morten Nielsen, Anders Smedegaard Bertelsen, Frene Hazell Ruta Zukauskaite Hansen et al. Acta Oncol. 2017

ACTAGICA



### Esophagus organ at risk doses Population mean DVH

- Autoplan selected in 31 of 32 pts
  - Reduction of lung dose

0.8

0.6

0.4

0.2

0⊾ 0

10

20

30

40

50

60

Relative volume, p-value

- No difference in heart dose
- Increased spinal canal dose

Mean DVH for heart





# Challenges using Autoplan



# PTV target in air or near surface

- GTV near surface  $\rightarrow$  3D printed bolus
- CTV near surface → crop CTV to under the skin or 3D printed bolus
- PTV near surface  $\rightarrow$  crop PTV to under the skin
  - Less robust to setup uncertainties, however VMAT treatment

### GTV near patient surface



### PTV near patient surface





# Large density differences in target areas

- Re-irradiation H&N cancer patient
- Danger of suboptimal beam fluence
- Hiding warnings of skin/density change boosts



#### Autoplan with density overwrite





# Large density differences in target areas

- Autoplan struggle with large density changes
  - Many pencil beam iteration
  - Difference between Collapsed-Cone and pencil beam calculation

Clinical plan





EUROPEAN SOCIETY FOR RADIOTHERAPY & ONCOLOGY

**Autoplan** 

# Overlapping PTVs with OAR



#### Geometric separation



# Overlapping PTVs with OAR

- PTV minimum 56.4 Gy (95% of prescription)
- Brainstem maximum 54 Gy
- PTV in brain stem minimum 51.3 Gy maximum 54 Gy



#### Autoplan no post optimisation





# Conformity around stereotactic targets

- Target doses with high homogeneity
- High conformity not easy
- No constraints close to target

#### SRS brain metastasis patient



#### SBRT lung cancer patient





### Multi center Autoplan study

The Netherlands Cancer Institute, The Netherlands Liverpool and Macarthur Cancer Therapy Centres, Australia Odense University Hospital, Denmark

Study setup

- Three local protocols
- Create Autoplan techniques
- Test on 3 pilot patients
- Validate on 10 patients

#### Conclusion

Techniques are adaptable • to multiple prostate radiotherapy protocols





# Challenges using Autoplan

- Target in air or near surface
- Large density differences in target a<sup>th</sup>
- Overlapping PTVs with OAR
- Conformity challenges for stereotact
- Using Autoplans across many center



• User knowledge of the Autoplanning process EUROPEAN SOCIETY FOR RADIOTHERAPY & ONCOLOGY



# How to implement AP in a new center

- Defined protocols
  - > Target
  - OAR threshold limits
  - Priority target/OAR's
- Replan group of patients
- Configure Autoplan according to protocol hours
- Reconfigure for specific needs:
  - Overlapping targets and OAR
  - Priorities between competing OAR
- Validate on separate patient group

- Check deliverability of plans
- Estimated time required 50
   hours



# Conclusion

- Autoplan create plans of high and often better quality than manual plans
- Reduces doses to OAR
- Removes inter planner variability
- The implementation is relatively easy
- Mind the pitfalls of Autoplan



### Thank you for your attention









Science in development 26-27 October 2018 Malaga, Spain

REGISTRATION OPENS Early May 2018

DEADLINES Contributions on ongoing research: 27 June 2018 Early registration: 21 August 2018

Late registration: 20 October 2018

No onsite registration.

optimal care, together

ESTRO 38

26-30 April 2019

Milan, Italy

#### DEADLINES

Abstract submission: 22 October 2018

Early registration: 16 January 2019

Late registration: 26 March 2019

#### WWW.ESTRO.ORG



